{"id":890187,"date":"2025-09-29T10:58:23","date_gmt":"2025-09-29T14:58:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-appoints-dr-ted-w-love-as-lead-independent-director\/"},"modified":"2025-09-29T10:58:23","modified_gmt":"2025-09-29T14:58:23","slug":"royalty-pharma-appoints-dr-ted-w-love-as-lead-independent-director","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-appoints-dr-ted-w-love-as-lead-independent-director\/","title":{"rendered":"Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">NEW YORK, Sept.  29, 2025  (GLOBE NEWSWIRE) &#8212; Royalty Pharma plc (Nasdaq: RPRX) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director. Dr. Love will continue to Chair the Nominating and Corporate Governance Committee.<\/p>\n<p>\u201cI am delighted to welcome Ted to the key role of Lead Independent Director,\u201d said Pablo Legorreta, Chief Executive Officer of Royalty Pharma and Chairman of the Board. \u201cTed has extensive research-based biopharma experience gained over a long and successful career and currently serves as Immediate Past Chairman of the Biotechnology Innovation Organization\u2019s (BIO) Board of Directors. Ted has consistently demonstrated exceptional judgment and leadership, and we look forward to his continued stewardship as we advance our mission to accelerate innovation in life sciences.\u201d<\/p>\n<p>\u201cI am honored to be appointed Lead Independent Director,\u201d said Ted. \u201cRoyalty Pharma\u2019s pioneering approach to life sciences innovation and its commitment to long-term value creation make it a remarkable organization. I look forward to continuing my contributions to the Board, providing independent oversight and helping to guide the company\u2019s strategic direction.\u201d<\/p>\n<p>\n        <strong>About Ted W. Love, MD<\/strong>\n      <\/p>\n<p>Dr. Love serves as BIO\u2019s Immediate Past Chair of its Board of Directors following a two-year term as Chairman (2023-2025). Previously, he served as President and CEO of Global Blood Therapeutics (GBT) as well as a member of its board. Before GBT, he was EVP, Research and Development and Technical Operations, at Onyx Pharmaceuticals. Prior to Onyx, Ted served as President, CEO and Chairman of Nuvelo. Earlier in his career, Ted served as SVP, Development, at Theravance and held a number of senior management positions in medical affairs and product development at Genentech, including as Chairman of Genentech\u2019s Product Development Committee and VP, Product Development. Dr. Love serves on the Board of Directors of Gilead Sciences and Structure Therapeutics. Ted holds an MD from Yale Medical School and a BA in molecular biology from Haverford College. He completed a residency in internal medicine and a fellowship in cardiology at the Massachusetts General Hospital.<\/p>\n<p align=\"justify\">\n        <strong>About Royalty Pharma <\/strong>\n      <\/p>\n<p>Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry\u2019s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly \u2013 directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma\u2019s current portfolio includes royalties on more than 35 commercial products, including Vertex\u2019s Trikafta, Johnson &amp; Johnson\u2019s Tremfya, GSK\u2019s Trelegy, Roche\u2019s Evrysdi, Servier\u2019s Voranigo, Biogen\u2019s Tysabri and Spinraza, AbbVie and Johnson &amp; Johnson\u2019s Imbruvica, Astellas and Pfizer\u2019s Xtandi, Pfizer\u2019s Nurtec ODT, and Gilead\u2019s Trodelvy, and 17 development-stage product candidates. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=01IXE0Z9Gp-BvmN1En5YbxD8wCot8d6xHCZ57STgCPib4p98uf_lKXtlU8-0O0vjyWROGxCUS_cuII4Ox2Bgvvs2dN-5WZzh70HPH_ppx2M=\" rel=\"nofollow\" target=\"_blank\">www.royaltypharma.com<\/a>.\u00a0\u00a0\u00a0<\/p>\n<p>\n        <strong>Royalty Pharma Investor Relations and Communications<\/strong>\n      <\/p>\n<p align=\"justify\">+1 (212) 883-6637<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5t2mAkWuWVGvDUY09kznQOUU0SAdXOvIUmzpCwoeiev8LBjp0mZ1zt0Oh8quRmn9qImxeGrDcwOWQgsl9COsiIM69MngbYQBAkCCoPk3dUc=\" rel=\"nofollow\" target=\"_blank\">ir@royaltypharma.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNjYzNyM3MTY5MzUyIzUwMDEwNTI2NA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NDc2ZGQ2M2EtOThjOS00NzdhLThlYWEtNWM1ZGMyZmQ2MzVhLTUwMDEwNTI2NC0yMDI1LTA5LTI5LWVu\/tiny\/Royalty-Pharma-plc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) &#8212; Royalty Pharma plc (Nasdaq: RPRX) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director. Dr. Love will continue to Chair the Nominating and Corporate Governance Committee. \u201cI am delighted to welcome Ted to the key role of Lead Independent Director,\u201d said Pablo Legorreta, Chief Executive Officer of Royalty Pharma and Chairman of the Board. \u201cTed has extensive research-based biopharma experience gained over a long and successful career and currently serves as Immediate Past Chairman of the Biotechnology Innovation Organization\u2019s (BIO) Board of Directors. Ted has consistently demonstrated exceptional judgment and leadership, and we look forward to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-appoints-dr-ted-w-love-as-lead-independent-director\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-890187","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-appoints-dr-ted-w-love-as-lead-independent-director\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) &#8212; Royalty Pharma plc (Nasdaq: RPRX) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director. Dr. Love will continue to Chair the Nominating and Corporate Governance Committee. \u201cI am delighted to welcome Ted to the key role of Lead Independent Director,\u201d said Pablo Legorreta, Chief Executive Officer of Royalty Pharma and Chairman of the Board. \u201cTed has extensive research-based biopharma experience gained over a long and successful career and currently serves as Immediate Past Chairman of the Biotechnology Innovation Organization\u2019s (BIO) Board of Directors. Ted has consistently demonstrated exceptional judgment and leadership, and we look forward to &hellip; Continue reading &quot;Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-appoints-dr-ted-w-love-as-lead-independent-director\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-29T14:58:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNjYzNyM3MTY5MzUyIzUwMDEwNTI2NA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-appoints-dr-ted-w-love-as-lead-independent-director\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-appoints-dr-ted-w-love-as-lead-independent-director\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director\",\"datePublished\":\"2025-09-29T14:58:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-appoints-dr-ted-w-love-as-lead-independent-director\\\/\"},\"wordCount\":548,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-appoints-dr-ted-w-love-as-lead-independent-director\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzNjYzNyM3MTY5MzUyIzUwMDEwNTI2NA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-appoints-dr-ted-w-love-as-lead-independent-director\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-appoints-dr-ted-w-love-as-lead-independent-director\\\/\",\"name\":\"Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-appoints-dr-ted-w-love-as-lead-independent-director\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-appoints-dr-ted-w-love-as-lead-independent-director\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzNjYzNyM3MTY5MzUyIzUwMDEwNTI2NA==\",\"datePublished\":\"2025-09-29T14:58:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-appoints-dr-ted-w-love-as-lead-independent-director\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-appoints-dr-ted-w-love-as-lead-independent-director\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-appoints-dr-ted-w-love-as-lead-independent-director\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzNjYzNyM3MTY5MzUyIzUwMDEwNTI2NA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzNjYzNyM3MTY5MzUyIzUwMDEwNTI2NA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-appoints-dr-ted-w-love-as-lead-independent-director\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-appoints-dr-ted-w-love-as-lead-independent-director\/","og_locale":"en_US","og_type":"article","og_title":"Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director - Market Newsdesk","og_description":"NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) &#8212; Royalty Pharma plc (Nasdaq: RPRX) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director. Dr. Love will continue to Chair the Nominating and Corporate Governance Committee. \u201cI am delighted to welcome Ted to the key role of Lead Independent Director,\u201d said Pablo Legorreta, Chief Executive Officer of Royalty Pharma and Chairman of the Board. \u201cTed has extensive research-based biopharma experience gained over a long and successful career and currently serves as Immediate Past Chairman of the Biotechnology Innovation Organization\u2019s (BIO) Board of Directors. Ted has consistently demonstrated exceptional judgment and leadership, and we look forward to &hellip; Continue reading \"Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-appoints-dr-ted-w-love-as-lead-independent-director\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-29T14:58:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNjYzNyM3MTY5MzUyIzUwMDEwNTI2NA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-appoints-dr-ted-w-love-as-lead-independent-director\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-appoints-dr-ted-w-love-as-lead-independent-director\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director","datePublished":"2025-09-29T14:58:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-appoints-dr-ted-w-love-as-lead-independent-director\/"},"wordCount":548,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-appoints-dr-ted-w-love-as-lead-independent-director\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNjYzNyM3MTY5MzUyIzUwMDEwNTI2NA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-appoints-dr-ted-w-love-as-lead-independent-director\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-appoints-dr-ted-w-love-as-lead-independent-director\/","name":"Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-appoints-dr-ted-w-love-as-lead-independent-director\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-appoints-dr-ted-w-love-as-lead-independent-director\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNjYzNyM3MTY5MzUyIzUwMDEwNTI2NA==","datePublished":"2025-09-29T14:58:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-appoints-dr-ted-w-love-as-lead-independent-director\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-appoints-dr-ted-w-love-as-lead-independent-director\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-appoints-dr-ted-w-love-as-lead-independent-director\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNjYzNyM3MTY5MzUyIzUwMDEwNTI2NA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNjYzNyM3MTY5MzUyIzUwMDEwNTI2NA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-appoints-dr-ted-w-love-as-lead-independent-director\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/890187","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=890187"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/890187\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=890187"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=890187"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=890187"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}